CT-P13 SC Auto-Injector + Placebo Auto-Injector
Phase 3Active 0 views this week 0 watching⚡ Active
Interest: 44/100
44
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Moderately to Severely Active Rheumatoid Arthritis
Conditions
Moderately to Severely Active Rheumatoid Arthritis
Trial Timeline
Jan 3, 2025 → Apr 15, 2026
NCT ID
NCT06738719About CT-P13 SC Auto-Injector + Placebo Auto-Injector
CT-P13 SC Auto-Injector + Placebo Auto-Injector is a phase 3 stage product being developed by Celltrion for Moderately to Severely Active Rheumatoid Arthritis. The current trial status is active. This product is registered under clinical trial identifier NCT06738719. Target conditions include Moderately to Severely Active Rheumatoid Arthritis.
What happened to similar drugs?
0 of 6 similar drugs in Moderately to Severely Active Rheumatoid Arthritis were approved
Approved (0) Terminated (0) Active (6)
Hype Score Breakdown
Clinical
17
Activity
12
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06738719 | Phase 3 | Active |
Competing Products
7 competing products in Moderately to Severely Active Rheumatoid Arthritis
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Afimkibart + Placebo | Chugai Pharmaceutical | Phase 3 | 47 |
| Afimkibart + Placebo | Chugai Pharmaceutical | Phase 3 | 44 |
| Afimkibart + Placebo | Chugai Pharmaceutical | Phase 3 | 47 |
| Afimkibart + Placebo | Roche | Phase 3 | 47 |
| Afimkibart | Roche | Phase 3 | 47 |
| Afimkibart | Roche | Phase 3 | 47 |
| Obefazimod | Abivax | Phase 2 | 39 |